AMRN - Amarin Corp.oration PLC

AMRN Stock Chart

AMRN Profile

Amarin Corporation plc, a pharmaceutical firm, focuses on advancing and marketing therapies for cardiovascular diseases across key global markets including the United States, Germany, Canada, Lebanon, and the United Arab Emirates. The company's flagship product, VASCEPA, is a prescription omega-3 fatty acid designed to lower triglyceride levels in adult patients with severe hypertriglyceridemia, complementing dietary efforts. Amarin primarily distributes its products through wholesalers and specialty pharmacy providers.

Beyond its core product, Amarin Corporation plc maintains a strategic collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug formulations and indications utilizing the active pharmaceutical ingredient in VASCEPA, eicosapentaenoic acid. This partnership aims to expand treatment options and market reach for cardiovascular therapies. Originally known as Ethical Holdings plc, the company rebranded to Amarin Corporation plc in 1999, reflecting its dedication to innovation and growth in the pharmaceutical sector.

Established in 1989 and headquartered in Dublin, Ireland, Amarin Corporation plc continues to drive advancements in cardiovascular care through research, development, and strategic partnerships. The company's commitment to improving patient outcomes underscores its position as a leader in the field of cardiovascular therapeutics, leveraging its expertise to address significant unmet medical needs globally.

AMRN Revenue Chart

AMRN Earnings

Analyst Ratings